Su-Eun Han, Mi-Gyeong Kim, Soondong Lee, Hee-Jeong Cho, Youngro Byun, Sujeong Kim, Young Bong Kim, Yongseok Choi and Yu-Kyoung Oh Initial preclinical safety of non-replicating human endogenous retrovirus envelope protein-coated baculovirus vector-based vaccines against human papillomavirus Journal of Applied Toxicology 33
Human endogenous retrovirus (HERV) envelope protein-coated, baculovirus vector-based HPV16L1 (AcHERV-HPV16L1) is a non-replicating DNA vaccine. AcHERV-HPV16L1 DNA vaccine did not cause significant changes in body weight. No hematological changes were observed on day 30 post-treatment. In a repeated-dose toxicity study, a transient decrease in the body weights was recovered by post-treatment day 20. Organ weights had normalized by day 30. A AcHERV-based HPV16L1 DNA vaccine demonstrated preclinical safety criteria in acute and range-finding toxicity studies.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf